Brought to you by 
Algeta chooses Bayer as global partner for Alpharadin
11 Dec 2015
Executive Summary
Norwegian biotech Algeta ASA has licensed Bayer Schering Pharma worldwide development and marketing rights to its Phase III cancer-targeting radiopharmaceutical Alpharadin (radium 223 chloride).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Algeta chooses Bayer as global partner for Alpharadin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice